The National Cancer Institute (NCI) established the AIDS and Cancer Specimen Resource (ACSR) in 1994 to support the collection and expert preservation of clinically-annotated biospecimens for multidisciplinary research, bridging laboratory basic science with clinical, behavioral, and epidemiological studies. For the past 19 years, the ACSR has provided the foundation for successful translational research reliant on consistent access to high-quality well-annotated biospecimens. It has accomplished this via development of extensive expertise in methods for specimen collection and maintenance including specimen stability and full functionality overtime. The ACSR remains crucial to HIV-translational research, expanding services to researchers, and instituting practices to complement innovative new experimental directions by global HIV investigators. Since 2008, the current grant cycle, ACSR banked over 50,000 and distributed over 10,000 biospecimens to scientists worldwide. ACSR has also developed unique programs, offering project consultation and researcher training at all levels that assist with specimen choice and inform about biorepository procedures, thus ensuring appropriate handling and use of valuable biospecimens for research. The work accomplished under the current ACSR will be leveraged and transitioned to achieve the Specific Aims for the new ACSR to: 1) develop and maintain the ACSR infrastructure that allows efficient translation of the overall ACSR mission (to support current and future trends in HIV/AIDS malignancy research) to an ongoing functional program 2) provide scientific leadership, expand utilization and relevance of the resource; 3) acquire, maintain and distribute a diverse collection of high-quality and well-annotated biospecimens and; 4) support initiatives, projects, programs and collections, both national and international through ACSR services. To accomplish these aims we will restructure the current ACSR to a single multisite ACSR, under the direction of the Office of the Chairs (OC) and administered by the Central Operations and Data Coordinating Center (CODCC) to be led by senior investigators in a shared leadership role, Drs. Michael McGrath and Sylvia Silver, representing the continuing UCSF and George Washington University (GW) Regional Biospecimen Repositories (RBR). The two original RBRs, UCSF and GW, account for > 80% of the overall ACSR inventory (500,000+ specimens) and for supplying 90% of the specimens disbursed to researchers in the past five years. The proposed ACSR also will add value through transitioning affiliate programs at the University of Arizona, Tucson, and Baylor College of Medicine to new RBRs. The ACSR will continue to evolve and streamline operations to incorporate a state of the art inventory system, and new technologies and methods to improve specimen viability. The ACSR is a dynamic entity that has used innovative and novel approaches to meet changes in the epidemic and research directions, and is well positioned to continue support of current and future trends in HIV research that will have a positive impact on diagnosis and management of HIV-malignancies worldwide.

Public Health Relevance

Cancer is now the leading cause of death in individuals infected with HIV and if we are to better understand the process of cancer development in the evolving HIV epidemic, high quality specimens must be available for research. The ACSR is committed to its mission to assist multidisciplinary research through careful collection and expert preservation of clinically-defined biological specimens that ensure translational research bridging laboratory basic science, clinical, behavioral, and epidemiological investigations. The ACSR as a resource maintains it success by: 1) providing guidance and training to national and international interested individuals and institutions and; 2) continuing t adapt its specimen acquisition to address changes in the HIV epidemic, in research needs and technological advances.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1CA181255-03
Application #
8920521
Study Section
Special Emphasis Panel (ZCA1-SRLB-5 (O2))
Program Officer
Liddell Huppi, Rebecca
Project Start
2013-09-23
Project End
2018-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
3
Fiscal Year
2015
Total Cost
$4,234,901
Indirect Cost
$756,293
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Castillo-Mancilla, Jose R; Morrow, Mary; Boum, Yap et al. (2018) Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. J Acquir Immune Defic Syndr 77:507-513
Lamers, Susanna L; Fogel, Gary B; Liu, Enoch S et al. (2018) Brain-specific HIV Nef identified in multiple patients with neurological disease. J Neurovirol 24:1-15
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Mwimanzi, Francis; Toyoda, Mako; Mahiti, Macdonald et al. (2018) Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. J Virol 92:
Ayers, Leona W; Barbachano-Guerrero, Arturo; McAllister, Shane C et al. (2018) Mast Cell Activation and KSHV Infection in Kaposi Sarcoma. Clin Cancer Res 24:5085-5097
Vasquez, Joshua J; Hussien, Rajaa; Aguilar-Rodriguez, Brandon et al. (2018) Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ. J Histochem Cytochem 66:427-446
Bebell, Lisa M; Siedner, Mark J; Musinguzi, Nicholas et al. (2017) Trends in one-year cumulative incidence of death between 2005 and 2013 among patients initiating antiretroviral therapy in Uganda. Int J STD AIDS 28:800-807
Lee, Guinevere Q; Bangsberg, David R; Mo, Theresa et al. (2017) Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. AIDS 31:2345-2354
Schneider, Johann W; Dittmer, Dirk P (2017) Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol 18:529-539
Yanik, Elizabeth L; Kaunitz, Genevieve J; Cottrell, Tricia R et al. (2017) Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. JAMA Oncol 3:974-978

Showing the most recent 10 out of 39 publications